Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

14 findings on how patients access online medical records, use technology

More than half of all patients have been offered online access to their medical records in 2017, an increase from 42 percent in 2014, according to a survey conducted by the HHS Office of the National Coordinator for Health Information Technology (ONC).

Thumbnail

Healthcare price growth hits 6-year high

Prices across the healthcare sector rose 2.2 percent year-over-year in March 2018, the highest annual growth rate recorded by Altarum since January 2012, with the report warning rapid price growth is likely to continue.

Microscopic probe takes internal images while measuring temperature

Researchers from the University of Adelaide have developed a microscopic probe capable of measuring temperatures while viewing the inside of the body. Study findings were published in the upcoming April 15 Optics Letters.

Thumbnail

Chicago’s Rush calls off merger with suburban hospital

The Rush hospital system based in Chicago has ended plans to acquire Little Company of Mary of Evergreen Park, Illinois, which would’ve merged 12 facilities with Rush University Medical Center and its 2,500-student health sciences college.

Thumbnail

Ex-Swedish Health surgeon suing Seattle Times over stories that led to his resignation

Johnny Delashaw, MD, the former chief of the Swedish Neuroscience Institute (SNI), is suing the Seattle Times over what he alleges was a “false and defamatory” investigative article that damaged his reputation and led to his resignation and the suspension of his medical license.

Thumbnail

Drug competition didn’t stop sharp increase in MS spending

The report from the Health Care Cost Institute (HCCI) examined claims for people with multiple sclerosis (MS) from 2009 to 2015 covered by individual market, employer-sponsored or Medicare Advantage plans. It found total spending per MS patient rose from around $23,900 to $39,628 by 2015. During the same time period, the share of spending spent towards injectable and oral disease modifying therapies (DMTs) rose from 39 percent to 53 percent.

Thumbnail

U.S. News adds patient reviews on doctor profile pages

U.S. News & World Report and Binary Fountain have announced a collaboration that will allow U.S. News to publish patient experience ratings on its doctor profile pages.

Money matters for recruiting young male doctors—but women value work/life balance more

What will keep early career physicians from leaving a hospital or health system may differ between men and women, according to a survey from CompHealth. Regardless of gender, most physicians said they’re finding jobs the old-fashioned way: referrals and networking.

Displaying 3641 - 3648 of 6654

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup